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per equivalents will be recouped in less than two months. Over 5 years there were 
325 fewer infections in the copper arm at a cost per QALY of £262.84. ConClusions: 
The investigation allowed the derivation of a spreadsheet-based model that uses 
the best current published information and shows the rapid ROI of a copper inter-
vention. It also calculates the impact on bed days and quality-adjusted life years 
(QALY). The model is simple, transparent to those with knowledge of spreadsheets, 
and allows adaptation to specific local settings.
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objeCtives: Patients with chronic obstructive pulmonary disease (COPD) are at risk 
of pneumococcal infection. A 13-valent pneumococcal-conjugate vaccine (PCV13) 
has recently been approved for adult protection against S. pneumoniae. This study 
estimated the clinical and economic consequences of vaccinating COPD patients 
aged ≥ 50 years with PCV13 compared to current vaccination recommendations using 
a 23-valent pneumococcal-polysaccharide vaccine, from the Spanish Healthcare 
System perspective. Methods: A microsimulation model with a Markov process 
accounting for risks and costs for invasive pneumococcal disease (IPD) and all-cause 
nonbacteremic pneumonia (NBP) was developed. Prevalence, mortality rates, vaccina-
tion and serotype coverage, and vaccination and disease-related costs (€ 2013) were 
based on published data. Vaccines effectiveness was modified by a waning effect 
over time. Herd-immunity and revaccination were not considered. Outcomes and 
costs (both discounted at 3%/year) were simulated 100 times with, 1.6 million COPD 
patients per simulation. Outcomes were pneumococcal cases averted and incremen-
tal cost–effectiveness ratio (ICER) in terms of cost per life-year gained (LYG). Sensitivity 
analyses were performed modifying the time horizon, discount rate and vaccination 
coverage. Results: Over a 5-year period, the use of PCV13 vs current vaccination 
strategy in adult COPD subjects would prevent 529 IPD cases, 6,329 inpatient-NBP 
cases, and 697 outpatient-NBP cases. Additionally, 231 IPD and 148 inpatient-NBP 
related deaths would be averted. The ICER was € 24,557/LYG for PCV13 vs current 
vaccination strategy. In sensitivity analyses, ICER ranged from € 26,986/LYG (when 
changing discount rate from 3% to 5%) to € 7,661/LYG (when changing vaccination 
coverage from 80% to 66%). Using a lifetime horizon 1,271 IPD cases, 10,294 inpatient-
NBP cases, and 2,072 outpatient-NBP cases would be prevented, with an ICER of € 5,030/
LYG. ConClusions: At a willingness-to-pay of € 30,000/LYG, PCV13 vaccination in 
COPD patients aged ≥ 50 years in Spain is a cost-effective strategy compared to cur-
rent vaccination recommendations under both 5-year and lifetime time horizons.
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objeCtives: Vancomycin has been the treatment of choice for several years while lin-
ezolid is a relatively new alternative in China. Although clinical superiority of linezolid 
was demonstrated in a recent head-to-head clinical study, economic evaluation com-
paring the two treatments provides additional useful decision making information. 
This study aimed to compare the cost-effectiveness of linezolid versus vancomycin 
in treating confirmed MRSA NP from a payer’s perspective in Nanjing. Methods: 
A cost-effectiveness model primarily driven by the head-to-head clinical data 
(Wunderink, CID: 2012), was adapted with local published data and expert opinion 
on resource use and unit costs. The model structure and assumptions were verified 
to reflect local clinical practice. Both linezolid and vancomycin arms were assumed 
to have same life expectancy in full health upon discharge. The base case analysis 
considered 10-day treatment duration for both treatments. Scenario analyses were 
conducted by varying treatment duration, per day total costs in ICU and general ward, 
drug acquisition costs, and including costs for managing key adverse events. All costs 
were reported in 2012 Chinese RMB. Results: A higher treatment success rate by 
2.7% was predicted for linezolid. Both treatment arms were estimated to have very 
similar average total costs in the region of RMB 78,800 with the key cost drivers being 
drug acquisition costs and ICU per day total cost. The ICER for linezolid was RMB 163 
for each additional successfully treated patient. Dominance of linezolid attributed to 
greater treatment success but lower total cost was observed in most of the scenario 
analyses. The highest ICER was RMB 31,663 in the scenario where the acquisition cost 
of vancomycin reduced by 20%. ConClusions: Given the estimated low ICERs with 
dominance in most of the scenario analyses, linezolid can be considered a cost effec-
tive option compared to vancomycin in managing confirmed MRSA NP in Nanjing.
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objeCtives: Ventilator-associated pneumonia (VAP) is the most common nosocomial 
infection in the intensive care unit (ICU). It’s associated with significant morbid-
ity, increasing the ICU and hospital length of stay (LOS), and raising overall costs. 
Literature suggests that costs could be reduced using the most efficient empiric 
recommendation on health care spending per QALY gained, PCV13 NIP in Czech 
Republic can be considered cost-effective.
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objeCtives: Fidaxomicin is the first in a new class of macrocylic antibiotics, indi-
cated in adults for the treatment of Clostridium difficile infections (CDI) also known 
as C. difficile-associated diarrhoea (CDAD). The study objective was to perform a 
cost-utility analysis of fidaxomicin for the treatment of CDI compared to oral met-
ronidazole (used to treat initial non-severe CDI and first non-severe recurrence) and 
oral vancomycin (used to treat severe CDI and any non-severe recurrence beyond 
the first one). Methods: A Markov model was used to determine the cost-utility 
of fidaxomicin in the treatment of all adult CDI patients (base case), patients with 
severe CDI, and patients with initial CDI recurrences, respectively. The cycle length 
was 10 days. The patient enters the model in the CDI health state and is treated either 
with fidaxomicin, oral metronidazole or vancomycin for 10 days. The time horizon 
was one-year. Deterministic and probabilistic sensitivity analyses were performed. 
Health state utilities were derived from the literature. The perspective was that of 
the Irish Health Service Executive (HSE). Results: In the base case, fidaxomicin was 
dominant compared to current standard of care, resulting in cost savings of € 2,904 
and an incremental QALY gain of 0.031. The main drivers of cost-effectiveness were 
the reduction in rate of recurrence in patients treated with fidaxomicin and the cost 
of hospitalisation. Fidaxomicin was also found to be dominant for all patient sub-
groups. The ICERs were highly sensitive to recurrence rates. The probability of the 
cost-effectiveness of fidaxomicin in all CDI patients at a willingness to pay thresh-
old of € 45,000 per QALY gained was estimated to be approx. 82%. ConClusions: 
Fidaxomicin was dominant compared to current standard of care with an approx. 82% 
probability of being cost-effective in all CDI patients at a willingness to pay threshold 
of € 45,000 per QALY gained.
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objeCtives: To demonstrate the impact of influenza vaccination in currently non-rec-
ommended populations in the UK. To understand critical elements of influenza infec-
tion (herd-effect and productivity losses) and management of disease. Management 
includes direct medical, non-medical and indirect resources. Methods: A multi-
cohort, static, one-year Markov-model was constructed. Universal influenza mass 
vaccination of healthy individuals ≥ 6 months to ≤ 64 years was applied, using either 
trivalent (TIV) or quadrivalent (QIV) influenza vaccines. Current vaccination cover-
age rates for high risk persons were utilized as a proxy. Vaccine efficacy data were 
derived from Cochrane Databases (TIV) and meta-analyses (QIV). The impact of herd-
effect was evaluated by two different estimates from published literature, providing a 
range of results. A societal perspective was adopted and 2010 was the cost reference 
year. Results: Using the average influenza-B circulation and vaccine matching data 
of 2000 to 2010, between 71,000-82,000 additional cases will be prevented with QIV 
versus TIV in one influenza season. QIV is anticipated to prevent more medical vis-
its, complications, and hospitalisations (15,000-17,000); (8,000-9,300) and (889-1,044), 
respectively. QIV programme costs are higher due to acquisition costs compared to 
TIV, however influenza treatment and management costs are lower due to fewer 
cases/complications for direct medical, non-medical and indirect categories (absen-
teeism/presenteeism), (savings: £4,800,000-£5,700,000); (savings: £215,000-£253,000); 
(savings: £22,400,000-£26,400,000), respectively. In addition, future productivity losses 
caused by premature mortality are also minimized with maximal effect with QIV 
rather than TIV (savings: £5,100,000-£6,700,000). ConClusions: Herd-effect is a well 
understood and appreciated benefit of vaccinating children and mass vaccination 
within a population. This model suggests that there are vast benefits in universal 
mass vaccination of healthy persons in the UK with QIV instead of TIV, due to greater 
health-related benefits and lower treatment-related costs. However, vaccine acquisi-
tion costs need to be considered.
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objeCtives: Health Economics evaluations are typically applied to medications or 
surgery costs, but this unique study has investigated the economic benefits of dis-
crete deployment of antimicrobial copper alloy touch surfaces in ICUs. Copper/cop-
per alloy surfaces have been shown to act as an adjunct to standard infection control 
practices in diverse clinical settings, continuously reducing contamination by over 
90%. A study by Salgado in 2013 investigated the use of copper surfaces in ICUs and 
reported a 58% reduction in hospital acquired infections. This study investigates the 
cost-effectiveness of this intervention. Methods: Following an extensive literature 
review and use of expert opinion a number of factors have been considered in this 
evaluation. These are the component costs of the items used in the ICU, the cost of 
and extra day in bed due to an infection, baseline infection rates and risk reduction 
of copper items. The model is based on a single room configuration in an intensive 
care unit with 20 beds in the UK using 6 critical items - bed rails, overbed tray table, 
chair, call button, data device and IV pole. The model has been created to show the 
economic impact of an environmental intervention. Results: The model predicts 
the cost of replacing key, frequently-touched surfaces in a 20-bed UK ICU with cop-
